Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Capital Expenditures (2024 - 2025)

Indivior Pharmaceuticals has reported Capital Expenditures over the past 2 years, most recently at $24.0 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $24.0 million for Q4 2025, up 50.0% from a year ago — trailing twelve months through Dec 2025 was $66.0 million (up 127.59% YoY), and the annual figure for FY2025 was $66.0 million, up 127.59%.
  • Capital Expenditures for Q4 2025 was $24.0 million at Indivior Pharmaceuticals, up from $20.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for INDV hit a ceiling of $24.0 million in Q4 2025 and a floor of $2.0 million in Q1 2024.